WO2026104891 - MULTI-VALENT ANTI-C5 MOLECULES
National phase entry is expected:
Publication Number
WO/2026/104891
Publication Date
21.05.2026
International Application No.
PCT/IB2025/000622
International Filing Date
18.11.2025
Title **
[English]
MULTI-VALENT ANTI-C5 MOLECULES
[French]
MOLÉCULES ANTI-C5 MULTIVALENTES
Applicants **
OAK BAY BIOSCIENCES INC.
Inventors
ERICKSON, Carl
RICHARDSON, Nigel
Priority Data
63/722,007
18.11.2024
US
63/763,760
26.02.2025
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4342 | |
| EPO | Filing, Examination, Granting | 60499 | |
| Japan | Filing, Examination, Granting | 3945 | |
| South Korea | Filing, Examination, Granting | 6026 | |
| USA | Filing, Examination, Granting | 17740 |
Total:
92,552
Contact Us
Abstract[English]
Provided herein are methods and compositions for the inhibition complement component (C5). The methods and compositions involve the use of aptamer-containing molecules, comprising one or more moieties that bind to and inhibit C5. The application further provides aptamer-containing molecules for the treatment of retinal diseases and/or hematological diseases.[French]
L'invention concerne des procédés et des compositions pour l'inhibiteur du complément 5 (C5). Les procédés et les compositions impliquent l'utilisation de molécules contenant des aptamères, comprenant une ou plusieurs fractions qui se lient à C5 et l'inhibent. L'invention concerne en outre des molécules contenant des aptamères pour le traitement de maladies rétiniennes et/ou de maladies hématologiques.